Immutep Financials
| PRRUF Stock | USD 0.26 0.00 0.00% |
Immutep |
Understanding current and past Immutep Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Immutep's financial statements are interrelated, with each one affecting the others. For example, an increase in Immutep's assets may result in an increase in income on the income statement.
The data published in Immutep's official financial statements typically reflect Immutep's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Immutep's quantitative information. For example, before you start analyzing numbers published by Immutep accountants, it’s essential to understand Immutep's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.
Please note, the presentation of Immutep's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Immutep's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Immutep's management manipulating its earnings.
Immutep Stock Summary
Immutep competes with Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and Moderna. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia. Immutep operates under Biotechnology classification in the United States and is traded on OTC Exchange.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Australia Square, Sydney, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | NYSE Composite |
| Website | www.immutep.com |
| Phone | 61 2 8315 7003 |
| Currency | USD - US Dollar |
Immutep Key Financial Ratios
There are many critical financial ratios that Immutep's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Immutep Limited reports annually and quarterly.| Return On Equity | -0.38 | |||
| Return On Asset | -0.23 | |||
| Number Of Employees | 17 | |||
| Beta | 1.95 | |||
| Z Score | 47.2 |
Immutep Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Immutep's current stock value. Our valuation model uses many indicators to compare Immutep value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Immutep competition to find correlations between indicators driving Immutep's intrinsic value. More Info.Immutep Limited is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Immutep's earnings, one of the primary drivers of an investment's value.Immutep Limited Systematic Risk
Immutep's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Immutep volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Immutep Limited correlated with the market. If Beta is less than 0 Immutep generally moves in the opposite direction as compared to the market. If Immutep Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Immutep Limited is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Immutep is generally in the same direction as the market. If Beta > 1 Immutep moves generally in the same direction as, but more than the movement of the benchmark.
Immutep June 15, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Immutep help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Immutep Limited. We use our internally-developed statistical techniques to arrive at the intrinsic value of Immutep Limited based on widely used predictive technical indicators. In general, we focus on analyzing Immutep Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Immutep's daily price indicators and compare them against related drivers.
| Information Ratio | 0.0594 | |||
| Maximum Drawdown | 8.33 |
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |